Could hepatitis B vaccine act as an adjuvant to lower risk and relapses of cancer?

Altinoz, Meric A; Ozpinar, Aysel; Ozpinar, Alp; Hacker, Emily; Elmaci, Ilhan

Altinoz, Meric A; Ozpinar, Aysel; Ozpinar, Alp; Hacker, Emily; Elmaci, Ilhan.

Afiliação

Altinoz MA; Department of Medical Biochemistry, Acibadem University, Istanbul, Turkey.
Ozpinar A; Department of Medical Biochemistry, Acibadem University, Istanbul, Turkey.
Ozpinar A; School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Hacker E; School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Elmaci I; Department of Neurosurgery, Acibadem University, Istanbul, Turkey.

Clin Exp Pharmacol Physiol ; 46(8): 694-704, 2019 08.

Article em En | MEDLINE | ID: mdl-31002181

Assuntos

Adjuvantes Imunológicos/farmacologia; Vacinas contra Hepatite B/farmacologia; Neoplasias/prevenção & controle; Animais; Humanos; Neoplasias/diagnóstico; Neoplasias/imunologia; Neoplasias/terapia; Recidiva; Risco

Palavras-chave

cancer; glioma; immune; vaccine optimization

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adjuvantes Imunológicos / Vacinas contra Hepatite B / Neoplasias Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google